Daniel Wynn, MD
Neurology · Northbrook, ILNPI 1710971700
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $575,365 of the $812,380 with a category attached, or 70.8%. 60 manufacturers reported payments, led by Sanofi at 27.8% of the total. Reporting peaked in 2019 at $217,634 and has fallen 68.7% since, to $68,094 in 2025. Among neurology clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,914 payments — averaging $278.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$226K
- EMD Serono, Inc.$199K
- E.r. Squibb & Sons, L.L.C.$92K
- AbbVie$31K
- Amgen$28K
- Bristol Myers Squibb$27K
- plus $209K from 54 others
Across 870 payments — averaging $15,122 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$7.7M
- Sanofi$2.7M
- F. Hoffmann-la Roche AG$498K
- Adamas Pharmaceuticals, Inc.$494K
- TG Therapeutics, Inc.$475K
- Eli Lilly$416K
- plus $864K from 14 others
What the payments were for
- Consulting fees$128,74916%
- Speaking & faculty fees$575,36571%
- Travel & lodging$53,3237%
- Food & beverage$54,2567%
- Education$6460%
- Gifts$410%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Mavenclad$176,421
- AUBAGIO$117,332
- ZEPOSIA$107,004
- LEMTRADA$50,561
- UPLIZNA$26,355
- ACTHAR$24,764
- UBRELVY$21,520
- NUEDEXTA$21,285
- BRIUMVI$16,930
- Yupelri$15,180
- AJOVY$14,498
- Ponvory$13,615
- OCREVUS$13,175
- Glatiramer Acetate$9,088
- Bafiertam$9,000
- Epidiolex$6,274
- Rebif$6,141
- PURIFIED CORTROPHIN GEL$5,623
- KESIMPTA$4,603
- MAYZENT$2,394
How this compares
$812,380 in reported general payments places this provider in the 95th percentile of 790 neurology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RebifInterferon Beta-1a/Albumin | 85 | $927,046 |
| Teriflunomide | 135 | $566,628 |
| CopaxoneGlatiramer Acetate | 56 | $404,050 |
| ZeposiaOzanimod Hydrochloride | 23 | $323,300 |
| AubagioTeriflunomide | 17 | $299,920 |
| Kesimpta PenOfatumumab | 25 | $218,922 |
| NuedextaDextromethorphan Hbr/Quinidine | 92 | $181,898 |
| VumerityDiroximel Fumarate | 18 | $151,968 |
| GlatopaGlatiramer Acetate | 42 | $89,997 |
| Dalfampridine ErDalfampridine | 95 | $89,713 |
| Glatiramer Acetate | 49 | $83,229 |
| BotoxOnabotulinumtoxina | 29 | $58,295 |
| HorizantGabapentin Enacarbil | 26 | $44,265 |
| Emgality PenGalcanezumab-Gnlm | 21 | $31,774 |
| NeuproRotigotine | 12 | $23,271 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| EMD Serono, Inc.Rebif | $198,867 | $927,04685 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $16,522 | $404,05056 claims |
| E.r. Squibb & Sons, L.L.C.Zeposia | $92,330 | $323,30023 claims |
| SanofiAubagio | $225,769 | $299,92017 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $22,491 | $181,89892 claims |
| BiogenVumerity | $749 | $151,96818 claims |
| Mylan Institutional Inc.Glatiramer Acetate | $2,231 | $83,22949 claims |
| AbbVieBotox | $30,625 | $58,29529 claims |
| Arbor Pharmaceuticals, Inc.Horizant | $282 | $44,26526 claims |
| UCB, Inc.Neupro | $2,069 | $23,27112 claims |
| Acorda Therapeutics, IncInbrija | $237 | $18,70113 claims |
| PfizerNurtec Odt | $1,188 | $17,65411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 790 neurology providers in Illinois.
Other neurology in Northbrook
- Augusto MiravalleChicago$1.4M
- Lori GuytonHerrin$1.1M
- Arthur ItkinPalos Heights$808K
- Andrew GordonLake Barrington$765K
- Martha McGrawWinfield$625K
- Reuben ValenzuelaPeoria$590K
- Adil JavedChicago$584K
- Tyler KaplanMaywood$549K
- Danny BegaChicago$442K
- Michael SmithChicago$382K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.